In the latest of a series of deals in what many industry executives and analysts consider to be the next blockbuster device product market, Boston Scientific Corp. became the third major vascular player to buy its way into the renal denervation (RDN) space with its recent acquisition of Vessix Vascular Inc. for a sum that could amount to $425 million. [See Deal] With this deal, Boston Scientific joins Medtronic PLC, which led the way in 2010 with its stunning potentially billion dollar acquisition of Ardian [See Deal], followed earlier this year by Medtronic Minimally Invasive Therapies’s acquisition of Maya Medical Inc.[See Deal]
It’s perhaps not surprising that strategics have acted quickly in a market that some analysts predict will hit $2 billion...